Ku ya 1 Gicurasi 2025, Hansoh Pharmaceutical yatangaje ko umuti wa B7-H4-target antibody-drug conjugate (ADC) HS-20089 wikoreye itsinda wo guterwa inshinge wahawe uburenganzira bwo gushyirwa mu bwoko bwa Breakthrough-Therapy-Designed Medicine n’Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) mu Bushinwa, hamwe n’ikimenyetso cyatanzwe ku barwayi ba kanseri y’intanga ngore isubira inyuma, kanseri y’imiyoboro y’inda cyangwa kanseri y’imbere mu nda.
Iyi ngingo ishyigikiwe n'ibyavuye mu bushakashatsi bwa Phase I HS-20089-101 n'ubushakashatsi bwa Phase II HS-20089-201. Ubushakashatsi bwa HS-20089-101 ni igerageza ry'ubuvuzi ry'icyiciro cya mbere rigizwe n'ibice byinshi, rifunguye, rigamije gusuzuma umutekano, ubushobozi bwo kwihanganira indwara, n'ubushobozi bwa HS-20089 mu gutera inshinge ku barwayi bafite ibibyimba bikomeye. Ubushakashatsi bwa HS-20089-201 ni igerageza ry'ubuvuzi ry'icyiciro cya kabiri rigizwe n'ibice byinshi, rifunguye, rigamije gusuzuma akamaro, umutekano, imiterere y'imiti, n'ubushobozi bwo kwirinda indwara bwa HS-20089 mu mitsi ku barwayi barwaye kanseri y'intanga isubira cyangwa yanduye ndetse na kanseri y'intanga ngabo.
HS-20089 ni ADC igamije B7-H4 ifite umutwaro wo gukumira indwara ya topoisomerase inhibitor (TOPOi) irimo gukorwa kugira ngo ivure kanseri y'intanga ngore n'izindi kanseri z'abagore mu magerageza menshi yo kwa muganga mu Bushinwa, aho ubushakashatsi bwakozwe cyane ari ikizamini cya gatatu cy'ubuvuzi. B7-H4 ni glycoprotein yo mu bwoko bwa transmembrane immune checkpoint igaragara cyane mu tumori twinshi, harimo kanseri y'intanga ngore na kanseri y'intanga ngore, ariko ikaba idakora neza mu ngingo zisanzwe.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Imeri:myimmnet@163.com
Igihe cyo kohereza: Gicurasi-09-2025